CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
Oxytocin +1 moredrug
Likely dose
Oxytocin 24 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02671266
NCT02671266Phase 2Completed
CompareCT.gov

Effect of Intranasal Oxytocin on Social Cognition

Massachusetts General Hospital·interventional·Posted Feb 2, 2016·Updated Nov 23, 2018

In Brief

A Phase 2 clinical trial evaluating Oxytocin and Placebo for Body Dysmorphic Disorder and Obsessive-compulsive Disorder. Completed, enrolled 41 participants across 1 site.

Detailed Summary

The purpose of the current study is to investigate the effect of an acute administration of intranasal oxytocin, relative to placebo, on social cognitive impairments among individuals with body dysmorphic disorder and obsessive-compulsive disorder, compared to healthy controls.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBody Dysmorphic Disorder, Obsessive-compulsive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2, 2016
Enrollment StartDec 1, 2014
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.4 years ago

Interventions

Oxytocindrug

Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.

Placebodrug

Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.